| Type: | combo |
| Component1: | Pioglitazone |
| Class1: | Thiazolidinedione |
| Component2: | Metformin |
| Class2: | Biguanide |
| Tradename: | Actoplus Met, Piomet, Politor, others |
| Dailymedid: | Pioglitazone and metformin |
| Routes Of Administration: | By mouth |
| Atc Prefix: | A10B |
| Atc Suffix: | D05 |
| Legal Uk: | POM |
| Legal Uk Comment: | [1] |
| Legal Us: | Rx-only |
| Legal Eu: | Rx-only |
| Legal Status: | Rx-only |
| Cas Number: | 737811-27-7 |
| Kegg: | D09744 |
Pioglitazone/metformin, sold under the brand name Actoplus Met among others, is a fixed-dose combination anti-diabetic medication used to improve glycemic control in adults with type 2 diabetes.[2] It contains pioglitazone, a thiazolidinedione, and metformin, a biguanide.[3]
Pioglitazone/metformin is indicated as an adjunct to diet and exercise:
Pioglitazone/metformin should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. There are no adequate and well-controlled studies in pregnant women with combination of pioglitazone and metformin or its individual components. It is not known whether pioglitazone and/or metformin are secreted in human milk. Because many drugs are excreted in human milk, pioglitazone/metformin should not be administered to a breastfeeding woman.
Pioglitazone/metformin should not be used in people with type 1 diabetes or for the treatment of diabetic ketoacidosis and should be used with caution in people with edema. Serum ALT levels should be evaluated prior to the initiation of therapy with combination of pioglitazone and metformin and periodically thereafter per the clinical judgment of the health care professional.
The most common side-effects are upper respiratory tract infection, diarrhea, combined edema/peripheral edema and headache, respectively. Most clinical adverse events were similar between groups treated with pioglitazone in combination with metformin and those treated with pioglitazone monotherapy.
Pioglitazone/metformin is contraindicated in people with known hypersensitivity to any components of this combination. These combination also contraindicated in renal disease which may also result from conditions, e.g., acute myocardial infarction, sepsis, acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
Pioglitazone/metformin may interact with furosemide, nifedipine, cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) and certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control (e.g., thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid).